Event Category: Pharma

2nd Expanded Access Programmes Global Congress 2022 Europe

London UK 

Expanded Access Programmes also known by other terms such as compassionate use, early access, managed access, named-patient access, or pre-approval access is a potential pathway for a patient with an immediately life-threatening illness or severely debilitating disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) before they are reviewed and approved by a regulatory authority.

When it is not possible for a patient to participate in a clinical trial and all other available medical options have been exhausted, the patient’s physician may seek special access to investigational medicine outside of the clinical trial setting. As investigational drugs have not yet received regulatory approval, it is very important to remember that their potential risks and benefits are not yet established. In general, the person and his or her doctor must apply for access to the investigational product, the company has to choose to cooperate, and the medicines regulatory agency needs to agree that the risks and possible benefits of the drug or device are understood well enough to determine if putting the person at risk has sufficient potential benefit.

Please click the link on the right to visit the Event Website or to Register

Co-located with 

The Expanded Access Programmes congress will be Co-located with the RWE, Market Access, Pricing & Reimbursement Congress.

Joint Networking at the Exhibit area.

Take advantage of networking with attendees and participants with receptive mindsets, from both events.

To find out about the range of branding, Exhibit, and Sponsorship Options, get in touch.

Sponsorship Opportunities: sponsor@paradigmglobalevents.com

For more information: info@paradigmglobalevents.com

Tel No: +44 (0) 207 193 3485

Register Now!

3rd Patient Centricity & Collaboration World Congress 2023 Americas, taking place in Washington, DC, USA

For more information click on the Website link on the right hand side.

To find out about the range of Branding, Exhibit, and Sponsorship Opportunities get in touch.

Sponsorship Opportunities: sponsor@paradigmglobalevents.com

For more information: info@paradigmglobalevents.com

Tel No: +44 (0) 207 193 3485

Save The Dates! Coming Soon!

18th Orphan Drugs & Rare Diseases Global Congress 2022 Americas

Boston, MA, USA

To find out about the range of Branding, Exhibit, and Sponsorship Opportunities get in touch.

Sponsorship Opportunities: sponsor@paradigmglobalevents.com

For more information: info@paradigmglobalevents.com

Tel No: +44 (0) 207 193 3485

Save The Dates! Coming Soon!

14th Biosimilars Global Congress 2022 Europe, will be taking place in London, United Kingdom.

To find out about the range of Branding, Exhibit, and Sponsorship Opportunities get in touch.

Sponsorship Opportunities: sponsor@paradigmglobalevents.com

For more information: info@paradigmglobalevents.com

Tel No: +44 (0) 207 193 3485

Save The Dates! Coming Soon!

2nd Patient Centricity & Collaboration World Congress 2022 Europe, taking place in Barcelona, Spain.

To find out about the range of Branding, Exhibit, and Sponsorship Opportunities get in touch.

Sponsorship Opportunities: sponsor@paradigmglobalevents.com

For more information: info@paradigmglobalevents.com

Tel No: +44 (0) 207 193 3485

Expanded Access Programmes Global Congress 2021 Americas

Expanded access or compassionate use is the use of an unauthorized drug or medical device under special forms of investigational new drug applications (IND) or IDE application for devices, outside of a clinical trial, by the patient with an immediately life-threatening illness or severely debilitating disease or condition who do not meet the enrollment criteria for the clinical trial in progress. These programs go under various names, including early access, special access, or managed access program, compassionate access, named-patient access, temporary authorization for use, cohort access, and pre-approval access.

When the patient participation in clinical trials is not possible due to ineligibility or scarcity of ongoing trials, or if enrollment in clinical trials is not conceivable because the distance to the trial inhibits access, expanded access offers a possible route for gaining access to an investigational medical product. These are investigational drugs, biologics, or medical devices that are being tested to see whether they are safe and effective. As investigational drugs have not yet received regulatory approval from FDA, the agency has not found these products to be safe or effective for their specific use. It is very important to remember that their potential risks and benefits are not yet established and their effectiveness to treat the condition is not yet known.

For more information: info@paradigmglobalevents.com

For sponsorship or exhibit Enquiry: sponsor@paradigmglobalevents.com

If you are interested in speaking at this event, please contact: jtr@paradigmglobalevents.com

Patient Centricity & Collaboration Global Congress 2021 Europe

Patient-centricity is a vital aspect in the research and development of biopharmaceutical products, disease management, designing a treatment, clinical trial, or other health solutions. In order to create a patient-centric solution, one must truly embrace a collaborative endeavor with the patient and their caregivers. Establishing a patient-centric solution involves getting feedback from real patients and their loved ones, and making decisions based on their medical conditions, experiences, needs, perspectives, and priorities.

The industry has come a long way with utilizing a patient-centered approach. The concept has gone from a buzzword to a potential trend, to a perceivable goal. Whilst the industry has advanced in recent years, the evolving healthcare model and ecosystem brought forward by advances in technology and more involved, empowered patients, means true patient centricity is a continuing quest and a compelling commitment.

We look forward at welcoming you to the congress!

For more information: info@paradigmglobalevents.com

For sponsorship or exhibit Enquiry: sponsor@paradigmglobalevents.com

If you are interested in speaking at this event, please contact: speak@paradigmglobalevents.com

15th Orphan Drugs & Rare Diseases Global Congress 2021 Americas – East Coast 

Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases Global Congress 2021 Americas. It’s the 15th in the series of our Flagship tri-annual Orphan Drugs & Rare Diseases event. This congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.

The COVID-19 Pandemic has impacted the lives of just about everyone, patients receiving continuous treatment and care included. The Rare Disease community is already experiencing considerable challenges in achieving early and detailed diagnosis and having access to care and life-saving treatment, to chronic, highly complex, progressive, and severely disabling nature of their diseases, which generate specific care needs. Undoubtedly, during this crisis, the rare diseases community is experiencing unprecedented overall disruption even more….

Please click the link on the right to visit the Event Website or to Register… >

16th Orphan Drugs & Rare Diseases Global Congress 2022 Europe

London, United Kingdom

Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases Global Congress 2022 Europe. It’s the 16th in the series of our Flagship tri-annual Orphan Drugs & Rare Diseases event. This congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.

The Conference will provide a unique platform for the convergence of stakeholders in the Orphan Drugs Industry to discuss and network with top-tier Government, Pharmaceuticals, Biotechs Non-Profit Organizations, Orphan Drugs Developers, Research Organizations as well as patient groups and advocates. We are putting together an agenda that addresses the driving macroeconomics factors, policies, and issues that will steer the development of Orphan Drugs Globally including access, commercialization, collaborations, policies, reimbursement, pricing, and much much more…

Please click the link on the right to visit the Event Website or to Register.

Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases 2019 Europe. It’s the 9th in the series of our Flagship tri-annual Orphan Drugs and Rare Diseases event, this congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.

In EU countries, any disease affecting fewer than 1 in 2,000 people is considered rare. That number may seem small, but it translates into approximately 246 000 people throughout the EU’s 28 member countries. Most patients suffer from even rarer diseases affecting 1 person in 100,000 or more.

There are more than 7,000 rare diseases identified, however, only a fraction of them have approve treatment available. “Orphan drugs” are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions. Currently, the regulatory climate is favourable with both FDA and European Medicines Agency, as they offer incentives, tax credits, user waivers and marketing exclusivity. As a result, the number of therapies approved for rare diseases for the past two decades has grown exponentially.

The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialisation, policies, reimbursement, pricing and more.

The two-day Congress will provide an interactive, cutting edge and comprehensive discussion and networking format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies and concepts surrounding orphan drugs and rare diseases.

More information coming soon!

At a global scale, pharmaceutical market is expected to grow in the years to come regardless of recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access of Pharmaceuticals to poor and middle-class families due to increases in disposable income also driving the growth of the industry. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments and regional authorities.

As healthcare budgets are continuously rising in Europe, governments implement a wide variety of policies to control them with the help of different public regulatory bodies that are involved in pharmaceutical coverage decisions across Europe. International collaboration among HTA and regulatory bodies can promote knowledge exchange, efficiency of information production and prepare developing systems for new challenges.

The upcoming 2020 Market Access, Pricing and Reimbursement Global Congress Europe will present a dynamic approach to key trends and insights on market access, health technology assessment, real world data, patient access, pricing and reimbursement on the current European landscape.

Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases Global Congress 2019 Americas. It’s the 11th in the series of our Flagship tri-annual Orphan Drugs and Rare Diseases event, this congress will provide you with current trends and innovations driving access to meet unmet medical  needs of rare disease patients.

Introducing a new format this year, we are putting together an agenda that addresses “Current Trends and Innovations driving access to meet unmet medical needs of rare disease patients”.

We have gathered together 50+, high caliber expert speakers to participate and share their knowledge and expertise through Panel discussions, keynote presentations, round table discussions and 4 major agenda streams addressing all aspect of the industry.

Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases 2019 Americas – West Coast. It’s the 10th in the series of our Flagship tri-annual Orphan Drugs and Rare Diseases event, this congress will provide you with a comprehensive insight in establishing well-informed strategic decisions.

The global rare disease diagnostics market was valued $45.18 billion in 2017 and is anticipated to reach $86.15 billion by 2025. Factors such as high incidence of rare diseases, presence of large numbers of research and development facilities for rare diseases, significant number of rare disease registries, high diagnosis rare of rare diseases in countries of North America, and extensive investments in different therapeutic areas are driving the growth of the North America rare disease diagnostics market. However, the Asia Pacific region is expected to register the highest CAGR of 9.22% during the forecast period 2018-2025.

The growth of the global orphan drugs market is increasing at a rapid pace due to the growing rare diseases. With further growth anticipated to meet the high unmet demand for more efficacious drugs with very little side effects. Although, the number of people affected by rare diseases are considerably low, the return of investment is high due to the high cost of orphan drugs. Global collaboration is also likely to fuel growth. FDA recognizes the significance of orphan drugs in the treatment of rare debilitating, life-threatening diseases therefore supporting stakeholders to promote research and development in this area.

However, the industry is never without its challenges. Factors such as the lack of diagnosis, government policies, awareness and funding for R&D, along with long diagnostic delays, high initial investment that leads to higher per patient treatment cost, reimbursement uncertainties and high cost of drug development are hindering the market.

Orphan Drugs & Rare Diseases 2019 Americas – West Coast will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organizations, orphan drugs developers as well as regional and local manufacturers.  We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialization, policies, reimbursement, pricing and more.

Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases 2020 Europe. It’s the 12th in the series of our Flagship tri-annual Orphan Drugs and Rare Diseases event, this congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.

The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, pharmaceuticals, biotechs, non-profit organisations, orphan drugs developers, research organizations as well as patient groups and advocates. We are putting together an agenda that address the driving macroeconomic factors, policies, and issues that will steer the development of orphan drugs globally including access, commercialisation, collaborations, policies, reimbursement, pricing and more.

More information coming soon

More information coming soon!

More information coming soon